TGTX
TGTX clinical trials: TG THERAPEUTICS, INC.
Every trial on ClinicalTrials.gov where TG THERAPEUTICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 51
- Trials linked
- 40
- As lead sponsor
- 11
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
TGTX on the catalyst calendar · TGTX registry changes
- Primary completion Dec 12, 2028Sponsor estimatePhase 2NCT07680946Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaTG Therapeutics, Inc. · SchizophreniaRecruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2028Sponsor estimatePhase 2NCT07673744A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in...TG Therapeutics, Inc. · Myasthenia GravisRecruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2039Sponsor estimateNo phase registeredNCT07577583Long-term Follow-up (LTFU) of Participants Who Received Azer-CelTG Therapeutics, Inc. · B-cell Mediated Autoimmune DisordersRecruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2027Sponsor estimatePhase 2NCT07503873A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and...TG Therapeutics, Inc. · Multiple SclerosisRecruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2030Sponsor estimatePhase 2/Phase 3NCT07220252Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisTG Therapeutics, Inc. · Relapsing Multiple SclerosisRecruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2035Sponsor estimateNo phase registeredNCT06433765A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)TG Therapeutics, Inc. · Multiple SclerosisRecruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2032Sponsor estimateNo phase registeredNCT06433752A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)TG Therapeutics, Inc. · Relapsing Multiple SclerosisRecruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2032Sponsor estimatePhase 3NCT04130997An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisTG Therapeutics, Inc. · Relapsing Multiple Sclerosis (RMS)Active, not recruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2026Sponsor estimatePhase 3NCT07211633A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in...TG Therapeutics, Inc. · Relapsing Multiple SclerosisActive, not recruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 1NCT06680037A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune DisordersTG Therapeutics, Inc. · B-cell Mediated Autoimmune DisordersRecruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2026Sponsor estimateNo phase registeredNCT06143514A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast MilkTG Therapeutics, Inc. · Relapsing Multiple SclerosisActive, not recruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 21, 2027Sponsor estimatePhase 3NCT05877963Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabTG Therapeutics, Inc. · Relapsing Multiple SclerosisRecruitingTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 22, 2023ActualPhase 3NCT02612311Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic...TG Therapeutics, Inc. · Chronic Lymphocytic LeukemiaTerminatedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 12, 2024ActualPhase 1NCT04806035Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaTG Therapeutics, Inc. · CLLTerminatedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2024ActualPhase 1NCT03671590Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesTG Therapeutics, Inc. · Non Hodgkin LymphomaTerminatedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 10, 2021ActualPhase 2NCT02742090Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyTG Therapeutics, Inc. · Chronic Lymphocytic LeukemiaTerminatedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 20, 2022ActualPhase 2/Phase 3NCT03801525Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in...TG Therapeutics, Inc. · Chronic Lymphocytic LeukemiaTerminatedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2024ActualPhase 1NCT03804996Study of TG-1801 in Subjects With B-Cell LymphomaTG Therapeutics, Inc. · B-Cell LymphomaCompletedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2022ActualPhase 2NCT04016805Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently...TG Therapeutics, Inc. · Chronic Lymphocytic LeukemiaTerminatedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 16, 2022ActualPhase 2NCT03828448Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTG Therapeutics, Inc. · Follicular LymphomaTerminatedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2022ActualPhase 2NCT03364231Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's LymphomaTG Therapeutics, Inc. · Marginal Zone LymphomaCompletedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 26, 2022ActualPhase 2NCT02656303A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in...TG Therapeutics, Inc. · Chronic Lymphocytic LeukemiaTerminatedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 11, 2022ActualPhase 2NCT03381170An Extension of the TG1101-RMS201 TrialTG Therapeutics, Inc. · Relapsing Remitting Multiple SclerosisCompletedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2015ActualPhase 1/Phase 2NCT01647971Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTG Therapeutics, Inc. · Non-Hodgkins LymphomaCompletedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 1/Phase 2NCT02013128Ublituximab + Ibrutinib in Select B-cell MalignanciesTG Therapeutics, Inc. · Chronic Lymphocytic LeukemiaCompletedTGTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 26 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner